IRWD
IRONWOOD PHARMACEUTICALS INC
Overview
Ironwood Pharmaceuticals develops and commercializes gastrointestinal and rare disease therapies. The company markets LINZESS (linaclotide) for irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation through partnerships with AbbVie, AstraZeneca, and Astellas in various territories.
IRONWOOD PHARMACEUTICALS INC is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $628.8M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
18 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-079 Q&A exchanges
- Q4 FY2025Earnings2026-02-2511 Q&A exchanges
- Q4 FY2024Earnings2025-02-2712 Q&A exchanges
- Q3 FY2024Earnings2024-11-0712 Q&A exchanges
- Q2 FY2024Earnings2024-08-0910 Q&A exchanges
- Q1 FY2024Earnings2024-05-0912 Q&A exchanges
- Q4 FY2023Earnings2024-02-159 Q&A exchanges
- Q3 FY2023Earnings2023-11-0910 Q&A exchanges
- Q2 FY2023Earnings2023-08-086 Q&A exchanges
- Q1 FY2023Earnings2023-05-067 Q&A exchanges
- Q4 FY2022Earnings2023-02-167 Q&A exchanges
- Q3 FY2022Earnings2022-11-036 Q&A exchanges
- Q2 FY2022Earnings2022-08-066 Q&A exchanges
- Q1 FY2022Earnings2022-05-0811 Q&A exchanges
- Q4 FY2021Earnings2022-02-1712 Q&A exchanges
- Q3 FY2021Earnings2021-11-0610 Q&A exchanges
- Q2 FY2021Earnings2021-08-0812 Q&A exchanges
- Q1 FY2021Earnings2021-05-066 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $0.26—Rev— vs ——EODHD
- Q1 FY20262026-05-12EPS$0.24 vs $-0.05+100.0%Rev$106.5M vs ——EODHD
- Q4 FY20252026-02-11EPS$-0.01 vs $0.02-100.0%Rev$47.7M vs ——EODHD
- Q3 FY20252025-11-09EPS$0.24 vs $0.11+100.0%Rev$122.1M vs ——EODHD
- Q2 FY20252025-08-10EPS$0.14 vs $0.03+100.0%Rev$85.2M vs ——EODHD
- Q1 FY20252025-05-06EPS$-0.14 vs $0.20-100.0%Rev$41.1M vs ——EODHD
- Q4 FY20242025-02-12EPS$0.02 vs $0.08-74.2%Rev$90.5M vs ——EODHD
- Q3 FY20242024-11-06EPS$0.02 vs $0.08-75.0%Rev$91.6M vs ——EODHD
- Q2 FY20242024-08-07EPS$-0.01 vs $0.15-100.0%Rev$94.4M vs ——EODHD
- Q1 FY20242024-05-08EPS$-0.02 vs $0.19-100.0%Rev$74.9M vs ——EODHD
- Q4 FY20232024-02-14EPS$-0.01 vs $0.21-100.0%Rev$117.6M vs ——EODHD
- Q3 FY20232023-11-08EPS$0.09 vs $0.16-43.8%Rev$113.7M vs ——EODHD
- Q2 FY20232023-08-07EPS$0.31 vs $0.25+24.0%Rev$107.4M vs ——EODHD
- Q1 FY20232023-05-03EPS$0.25 vs $0.24+4.2%Rev$104.1M vs ——EODHD
- Q4 FY20222023-02-15EPS$0.27 vs $0.270.0%Rev$107.2M vs ——EODHD
- Q3 FY20222022-11-02EPS$0.28 vs $0.27+3.7%Rev$108.6M vs ——EODHD
- Q2 FY20222022-08-03EPS$0.21 vs $0.30-30.0%Rev$97.2M vs ——EODHD
- Q1 FY20222022-05-04EPS$0.21 vs $0.26-19.2%Rev$97.5M vs ——EODHD
- Q4 FY20212022-02-16EPS$0.27 vs $0.35-22.9%Rev$117.1M vs ——EODHD
- Q3 FY20212021-11-03EPS$0.33 vs $0.31+6.5%Rev$103.7M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $0.26 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $0.24 | $-0.05 | +100.0% | $106.5M | — | — | EODHD |
| Q4 FY2025 | 2026-02-11 | $-0.01 | $0.02 | -100.0% | $47.7M | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $0.24 | $0.11 | +100.0% | $122.1M | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $0.14 | $0.03 | +100.0% | $85.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.14 | $0.20 | -100.0% | $41.1M | — | — | EODHD |
| Q4 FY2024 | 2025-02-12 | $0.02 | $0.08 | -74.2% | $90.5M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $0.02 | $0.08 | -75.0% | $91.6M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.01 | $0.15 | -100.0% | $94.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.02 | $0.19 | -100.0% | $74.9M | — | — | EODHD |
| Q4 FY2023 | 2024-02-14 | $-0.01 | $0.21 | -100.0% | $117.6M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $0.09 | $0.16 | -43.8% | $113.7M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $0.31 | $0.25 | +24.0% | $107.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $0.25 | $0.24 | +4.2% | $104.1M | — | — | EODHD |
| Q4 FY2022 | 2023-02-15 | $0.27 | $0.27 | 0.0% | $107.2M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $0.28 | $0.27 | +3.7% | $108.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $0.21 | $0.30 | -30.0% | $97.2M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $0.21 | $0.26 | -19.2% | $97.5M | — | — | EODHD |
| Q4 FY2021 | 2022-02-16 | $0.27 | $0.35 | -22.9% | $117.1M | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $0.33 | $0.31 | +6.5% | $103.7M | — | — | EODHD |
Source: EODHD. IRWD reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks IRWD's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 9/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.66 | $1.67 | -0.6% | +2.9% | +4.6% |
| Q4 FY2026 | $1.34 | $1.56 | -14.1% | +3.4% | +6.2% |
| Q3 FY2026 | $1.27 | $1.44 | -12.1% | +0.6% | +3.6% |
| Q2 FY2026 | $1.39 | $1.49 | -6.7% | +4.2% | +3.3% |
| Q1 FY2025 | $1.78 | $1.75 | +1.5% | -3.1% | -6.0% |
| Q4 FY2025 | $1.30 | $1.50 | -13.3% | -0.8% | -1.4% |
| Q3 FY2025 | $1.68 | $1.74 | -3.2% | +0.1% | +0.7% |
| Q2 FY2025 | $1.61 | $1.77 | -9.3% | -0.2% | -1.8% |
| Q1 FY2024 | $1.54 | $1.64 | -6.2% | -4.5% | -6.2% |
| Q4 FY2024 | $1.64 | $1.67 | -1.6% | +1.7% | +4.6% |
Guidance change history
Sample- Q1 FY2026Maintained2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Maintained2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Thomas A McCourtCEO1 yr 4 mo18 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
- Gregory S MartiniCFO1 yr 4 mo3 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last guidance cut Q2 FY2026
- Tammi L GaskinsChief Commercial Officer1 yr 3 mo1 callCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
- Minardo JohnChief Legal Officer1 yr 4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance cut Q3 FY2026
- Michael ShetzlineSVP, CMO, Head-Res&Drug1 yr 4 mo18 callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
- Ronald SilverPrincipal Accounting Officer1 yr 5 mono recorded callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • last guidance cut Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IRWD.
$ curl https://api.spokenalpha.com/v1/companies/IRWDFAQ
Frequently asked about IRWD
Where can I find IRONWOOD PHARMACEUTICALS INC's (IRWD) earnings call transcripts?
Spoken Alpha indexes IRWD's earnings call transcripts at https://spokenalpha.com/companies/IRWD. Each call links to attributed speakers and parsed analyst Q&A. IRONWOOD PHARMACEUTICALS INC's own investor relations page is at https://investor.ironwoodpharma.com/home/default.aspx.
When was IRONWOOD PHARMACEUTICALS INC's most recent earnings call?
IRONWOOD PHARMACEUTICALS INC (IRWD) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is IRWD in?
IRONWOOD PHARMACEUTICALS INC (IRWD) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).